3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Unknown
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Breast
1
Conditions
Brain Neoplasms
5
Breast Neoplasms
4
Meningeal Neoplasms
1
Meningeal Carcinomatosis
1
Interventions
Trastuzumab
2
Radiotherapy
2
Capecitabine
2
tucatinib
1
sapanisertib
1
pertuzumab
1
patritumab deruxtecan
1
paclitaxel-Angiopep-2 conjugate
1
omburtamab I-131
1
fludarabine
1
eribulin
1
avelumab
1
WP 744
1
Temozolomide
1
Spinal Puncture
1
Rituximab
1
Psychiatric Rehabilitation
1
Phlebotomy
1
Methotrexate
1
Cyclophosphamide
1
Amplified Fragment Length Polymorphism Analysis
1
AZD1390
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Meningeal Neoplasms
×
eribulin
×
CNS
×
Clear all
NCT03613181
2023-04-24
ANGLeD
Angiochem Inc
Phase 3
Unknown
150 enrolled